首页 > 市场调查报告书 > 医疗设备

妇科治疗

市场调查报告书

商品编码

1477217

子宫肌瘤治疗药物市场，按肌瘤类型，按药物类型，按配销通路，按地理位置

Uterine Fibroids Treatment Drugs Market, By Fibroid Type, By Drug Type, By Distribution Channel, By Geography

出版日期: 2024年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

子宫肌瘤治疗药物市场预计 2024 年价值 18.7 亿美元，预计到 2031 年将达到 31.9 亿美元，2024 年至 2031 年年复合成长率(CAGR) 为 7.9%。

报告范围		报告详情
基准年：	2023年	2024 年市场规模：	18.7 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测 2024 年至 2031 年复合年增长率：	7.90%	2031 年价值预测：	31.9 亿美元

图 1. 2024 年子宫肌瘤治疗药物市场占有率 (%)（按地区）

子宫肌瘤是女性子宫内或子宫上生长的非癌性肿瘤。肌瘤引起的症状严重程度各不相同，包括月经量多或疼痛、下腹部压力或疼痛、频尿等。手术治疗是一种选择，但存在风险。因此，无需手术即可缩小或消除肌瘤的药物疗法对许多患者来说是一个有吸引力的选择。随着研究人员致力于开发新疗法，全球子宫肌瘤治疗药物市场提供了充满希望的成长机会。

市场动态：

女性子宫肌瘤盛行率不断上升，加上对非侵入性治疗方案的需求，是推动子宫肌瘤治疗药物市场成长的关键因素。根据妇女健康办公室 2021 年 2 月发布的新闻稿，大约 20-80% 的女性在 50 岁时会患上肌瘤此外，与外科手术相关的局限性和风险正在进一步推动对药物疗法的研究。然而，药物开发的高成本构成了挑战。此外，发展中国家对肌瘤治疗方案缺乏认识也限制了市场扩张。同时，临床试验中新兴的口服疗法预计将提供新的机会。

研究的主要特点：

该报告对全球子宫肌瘤治疗药物市场进行了深入分析，并提供了预测期（2024-2031）的市场规模（十亿美元）和年复合成长率（CAGR%），以2023年为基准年。
它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数介绍了全球子宫肌瘤治疗药物市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球子宫肌瘤治疗药物市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球子宫肌瘤治疗药物市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 9 章：竞争格局

公司简介
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

第 10 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 11 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI6788

The uterine fibroids treatment drugs market is estimated to be valued at USD 1.87 Bn in 2024 and is expected to reach USD 3.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.87 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	7.90%	2031 Value Projection:	US$ 3.19 Bn

Figure 1.Uterine Fibroids Treatment Drugs Market Share (%), By Region, 2024

Uterine Fibroids Treatment Drugs Market - IMG1

Uterine fibroids are non-cancerous tumors that grow in or on a woman's uterus. Symptoms caused by fibroids vary in severity and include heavy or painful periods, pressure or pain in the lower abdomen, frequent urination, etc. Over-the-counter medications like ibuprofen can help relieve symptoms but do not address the underlying cause. Surgical procedures are an option but carry risks. Therefore, drug therapies that can shrink or eliminate fibroids without surgery present an attractive option for many patients. The global uterine fibroids treatment drugs market offers promising growth opportunities as researchers work to develop novel therapies.

Market Dynamics:

The growing prevalence of uterine fibroids among women coupled with the demand for non-invasive treatment options is a key factor fueling the uterine fibroids treatment drugs market growth. As per Office on Women's Health press release published in February 2021, around 20-80% women develop fibroids by the age of 50. Moreover, the limitations and risks associated with surgical procedures are further driving research into pharmaceutical therapies. However, the high costs involved in drug development pose a challenge. Additionally, lack of awareness about fibroid treatment options in developing nations also restrains market expansion. Meanwhile, emerging oral therapies in the clinical trial pipeline are expected to provide new opportunities.

Key Features of the Study:

This report provides an in-depth analysis of the global uterine fibroids treatment drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global uterine fibroids treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global uterine fibroids treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global uterine fibroids treatment drugs market.

Market Segmentation

Fibroid Type:
- Intramural fibroids
- Submucosal fibroids
- Subserosal fibroids
- Others
Drug Type:
- Gonadotropin-releasing hormone (GnRH) antagonists
- Gonadotropin-releasing hormone (GnRH) agonists
- Progesterone & Contraceptives
- Hormonal Medications
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Fibroid Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Uterine Fibroids Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Uterine Fibroids Treatment Drugs Market, By Fibroid Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Intramural fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Submucosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Subserosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Uterine Fibroids Treatment Drugs Market, By Drug Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Gonadotropin-releasing hormone (GnRH) antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Gonadotropin-releasing hormone (GnRH) agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Progesterone & Contraceptives
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Hormonal Medications
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Uterine Fibroids Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Uterine Fibroids Treatment Drugs Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Myovant Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics